Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Cure8 research brief
Why This Matters
People with IBD often have higher rates of anxiety and depression; this study suggests an experimental oral nanotherapy carrying apremilast might treat both gut inflammation and related neuropsychiatric symptoms in animal models by altering microbiota and reducing neuroinflammation.
That could point to future combined gut–brain treatment strategies, pending human studies.
Who Should Pay Attention
Researchers studying drug delivery, microbiome–gut–brain interactions, and preclinical IBD models; clinicians and patients interested in emerging therapies for IBD-related psychiatric symptoms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study tested a β-glucan–coated nanomicelle formulation carrying apremilast designed for oral delivery to inflamed colon in mouse colitis models.
The formulation reportedly improved drug retention in the gut, reduced intestinal damage, altered gut microbiota composition, lowered systemic and neuroinflammation, and lessened anxiety- and depression-like behaviors in mice with colitis. The work is preclinical (animal) research and does not represent clinical efficacy or safety in people with IBD.
Apremilast is being used in a novel formulation here; this is not an approved oral apremilast nanotherapy for IBD.
If you’re interested in emerging therapies or gut–brain links in IBD, this paper suggests a delivery-platform strategy that combines anti-inflammatory drug delivery with microbiome modulation, but human studies are needed before clinical relevance is established.
Keep In Mind
This is an abstract of preclinical (animal) research; results in mice do not ensure safety or efficacy in humans. The formulation uses apremilast in a novel nanoparticle and should not be interpreted as an available or approved treatment. Further work, including clinical trials, would be required.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAdvanced science (Weinheim, Baden-Wurttemberg, Germany)
AuthorsChandrashekhar Jori, Ahmed Shaney Rehman, Taruna Lamba +8 more
InstitutionChemical Biology Unit, Institute of Nano Science and Technology, Mohali, Punjab, India.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
Probiotic‐Derived Vesicles Rectally Delivered via Thermo‐Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor.
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...